Clinical trials & evidence

Alzheimer’s Research Moves Beyond Amyloid

CAR-T Starts Moving From Factory Medicine to In-Patient Engineering

AML’s Frontline Future Starts With Finding the Mutation Fast

Cellular Reprogramming Enters Neuro-Ophthalmology

Chronic pain may be a cardiovascular warning sign, not just a symptom

Alzheimer’s Agitation Moves Closer to a Phase 2 Readout

ALS Survival Data Return to the Evidence Debate

Could AI help prevent the next athlete cardiac tragedy? Evidence is moving faster than practice

Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
